Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CAR-NK-CD19 in Relapsed/Refractory B Lymphoid Malignancies
NCT04796675Phase 1Unknown
- Start
- Apr 2021
- Primary completion
- Mar 2023
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR-NK-CD19 in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). Primary endpoint: Incidence of Treatment-related Adverse Events at 2 years. Status: unknown.
02
Drugs
CAR-NK-CD19
03
Conditions
acute lymphoblastic leukemia (ALL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04796675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04796675.